BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of $18.72 billion. The enterprise value is $1.98 billion.
| Market Cap | 18.72B |
| Enterprise Value | 1.98B |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, before market open.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNTech SE has 237.73 million shares outstanding.
| Shares Outstanding | 237.73M |
| Owned by Insiders (%) | 62.83% |
| Owned by Institutions (%) | 18.58% |
| Float | 89.17M |
Valuation Ratios
The trailing PE ratio is 157.66 and the forward PE ratio is 7.04. BioNTech SE's PEG ratio is 0.04.
| PE Ratio | 157.66 |
| Forward PE | 7.04 |
| PS Ratio | 6.31 |
| Forward PS | 6.56 |
| PB Ratio | 0.87 |
| P/FCF Ratio | 3.52 |
| PEG Ratio | 0.04 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.98, with an EV/FCF ratio of 0.37.
| EV / Earnings | 16.14 |
| EV / Sales | 0.67 |
| EV / EBITDA | 4.98 |
| EV / EBIT | 10.26 |
| EV / FCF | 0.37 |
Financial Position
The company has a current ratio of 11.38, with a Debt / Equity ratio of 0.02.
| Current Ratio | 11.38 |
| Quick Ratio | 10.99 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 1.16 |
| Debt / FCF | 0.09 |
| Interest Coverage | 5.42 |
Financial Efficiency
Return on equity (ROE) is 0.60% and return on invested capital (ROIC) is -1.78%.
| Return on Equity (ROE) | 0.60% |
| Return on Assets (ROA) | 0.50% |
| Return on Capital (ROIC) | -1.78% |
| Revenue Per Employee | $483,769 |
| Profits Per Employee | $20,027 |
| Employee Count | 6,133 |
| Asset Turnover | 0.12 |
| Inventory Turnover | 1.46 |
Taxes
In the past 12 months, BioNTech SE has paid $36.12 million in taxes.
| Income Tax | 36.12M |
| Effective Tax Rate | 22.72% |
Stock Price Statistics
The stock price has decreased by -26.95% in the last 52 weeks. The beta is 0.27, so BioNTech SE's price volatility has been lower than the market average.
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -26.95% |
| 50-Day Moving Average | 91.71 |
| 200-Day Moving Average | 96.43 |
| Relative Strength Index (RSI) | 27.92 |
| Average Volume (20 Days) | 752,122 |
Short Selling Information
| Short Interest | 2.74M |
| Short Previous Month | 3.04M |
| Short % of Shares Out | 5.36% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.92 |
Income Statement
In the last 12 months, BioNTech SE had revenue of $2.97 billion and earned $122.83 million in profits. Earnings per share was $0.51.
| Revenue | 2.97B |
| Gross Profit | 2.33B |
| Operating Income | -506.49M |
| Pretax Income | 157.58M |
| Net Income | 122.83M |
| EBITDA | 397.82M |
| EBIT | 193.27M |
| Earnings Per Share (EPS) | $0.51 |
Balance Sheet
The company has $17.20 billion in cash and $461.45 million in debt, giving a net cash position of $16.74 billion or $70.42 per share.
| Cash & Cash Equivalents | 17.20B |
| Total Debt | 461.45M |
| Net Cash | 16.74B |
| Net Cash Per Share | $70.42 |
| Equity (Book Value) | 21.46B |
| Book Value Per Share | 90.29 |
| Working Capital | 17.92B |
Cash Flow
In the last 12 months, operating cash flow was $6.16 billion and capital expenditures -$846.59 million, giving a free cash flow of $5.31 billion.
| Operating Cash Flow | 6.16B |
| Capital Expenditures | -846.59M |
| Free Cash Flow | 5.31B |
| FCF Per Share | $22.35 |
Margins
Gross margin is 78.50%, with operating and profit margins of -17.07% and 4.14%.
| Gross Margin | 78.50% |
| Operating Margin | -17.07% |
| Pretax Margin | 5.31% |
| Profit Margin | 4.14% |
| EBITDA Margin | 13.41% |
| EBIT Margin | 6.51% |
| FCF Margin | 179.11% |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.36% |
| Shareholder Yield | 1.36% |
| Earnings Yield | 0.66% |
| FCF Yield | 28.38% |
Analyst Forecast
The average price target for BioNTech SE is $112.82, which is 43.25% higher than the current price. The consensus rating is "Buy".
| Price Target | $112.82 |
| Price Target Difference | 43.25% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 0.65% |
| EPS Growth Forecast (5Y) | -54.67% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 6.84 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.84 |
| Piotroski F-Score | 5 |